

Retail Health Clinics' Care Passes Limited Test

BY ALICIA AULT

Retail clinics appear to offer cost-effective, high-quality care, at least for three common conditions: urinary tract infections, otitis media, and pharyngitis, according to a recent study.

For insured patients, the cost of caring for these three illnesses was 30%-40% less at retail clinics than in physician offices and urgent care centers, and a

whopping 80% less than in emergency departments, according to researchers at the RAND Corp., the University of Pittsburgh, and HealthPartners Research Foundation of Minneapolis.

Care cost less at the retail clinics because they are reimbursed at a lower rate for evaluation and management and they order fewer tests and imaging studies, the authors wrote (*Ann. Intern. Med.* 2009;151:321-9). They analyzed claims

data from enrollees at HealthPartners, a Minneapolis-based health plan that covers care at retail clinics.

The study showed "that patients can feel safe in going to these retail health clinics for fairly limited, minor problems," Dr. Ted Epperly, president of the American Academy of Family Physicians, said in an interview. But the analysis did not show that retail clinics are appropriate for older patients who may

have more complex problems and a host of comorbidities, he said.

The study predominately covered enrollees who were aged 2-44 years, with a small percentage aged 45-64. There were only three enrollees over age 65 in the database. The authors compared the cost and quality of care and delivery of services for the three acute conditions in retail clinics with the cost and quality of care received in physician offices, urgent care centers, and emergency departments.

Dr. Yul D. Ejnes, a member of the American College of Physicians' board of regents and chair of the ACP's medical service committee, said he wasn't surprised by the findings for this population and for these three conditions.

But he said he did not think the findings would translate to older patients or even similar age groups at retail clinics elsewhere in the United States. Retail clinics began in Minnesota and are well-established there, according to the study authors.

The study is reassuring, Dr. Ejnes said in an interview, but "I don't think it puts



Cancer has never been treated this way before

OncologySTAT puts the most trusted information and tools for fighting cancer directly into the hands of oncology and hematology professionals!

Register today for **FREE** at www.oncologystat.com

SIGN UP
for free newsletters
summarizing
the week's
top oncology
stories!

Search and download recent articles from 100+ Elsevier cancer related journals and read professionally written daily summaries of articles from leading society journals like JCO, JNCI, CA, Blood, JAMA and NEJM

Read daily news and regulatory updates including *The Pink Sheet*

Access a professional drug monograph database and download NCCN approved chemotherapy regimens

Spotlight on Breast Cancer

Organize information and clinical tools by 27 cancer types from breast to uterine

The screenshot displays the OncologySTAT website with a navigation bar at the top. The main content area features several news articles with headlines such as "Adjuvant 5-FU Effective in Gastric Cancer", "GPC Biotech's Sarplata Falls SPARC Trial", and "New Glioblastoma Treatment Shows Promise". There are also sections for "CANCER TYPE SPOTLIGHTS" and "What Patients Are Reading". The interface is clean and professional, with clear headings and concise text.

OncologySTAT™
One Source, Many Resources.

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685). 1. Publication title: OB. GYN. NEWS. 2. Publication No. 0029-7437. 3. Filing date: October 01, 2009. 4. Issue frequency: Monthly. 5. No. of issues published annually: 14. 6. Annual subscription price: \$103.00. 7. Complete mailing address of known office of publication: International Medical News Group, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960. 8. Complete mailing address of headquarters or general business office of publisher: International Medical News Group, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960. 9. Full names and complete mailing addresses of Publisher, Editor, and Managing Editor: President, Alan J. Imhoff, IMNG, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960, Editor, Mark Jo M. Dales, IMNG, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, Managing Editor, Catherine Cooper Nellist, IMNG, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852. 10. Owner: Elsevier Inc., 360 Park Ave. South, New York, NY 10010. 11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None. 12. Tax Status: Not applicable. 13. Publication title: OB. GYN. NEWS. 14. Issue date for circulation data below: September 2009. 15. Extent and nature of circulation; Average no. copies each issue during preceding 12 months. a. Total number of copies: 38,146. b. Legitimate paid and/or requested distribution. (1) Individual Paid/Requested Mail subscriptions stated on PS Form 3541: 19,148. (2) Copies requested by employers for distribution to employees by name or position stated on PS Form 3541: 170. (3) Sales through dealers and carriers, street vendors, counter sales, and other paid distribution outside USPS: 0. (4) Requested copies distributed by other mail classes through the USPS: 98. c. Total paid and/or requested circulation: 19,416. d. Nonrequested distribution. (1) Nonrequested mail subscriptions stated on PS Form 3541: 18,689. (2) Nonrequested copies distributed through the USPS by other classes of mail: 0. (3) Nonrequested copies distributed outside the mail: 12. e. Total nonrequested distribution: 18,701. f. Total distribution: 38,117. g. Copies not distributed: 199. h. Total: 38,317. i. Percent paid and/or requested circulation: 50.94%. No. copies of single issue published nearest to filing date. a. Total numbers of copies: 37,504. b. Legitimate paid and/or requested distribution. (1) Individual Paid/requested mail subscriptions stated PS Form 3541: 17,487. (2) Copies requested by employers for distribution to employees by name or position stated on PS Form 3541: 253. (3) Sales through dealers and carriers, street vendors, counter sales, and other paid distribution outside USPS: 0. (4) Requested copies distributed by other mail classes through the USPS: 133. c. Total paid and/or requested circulation: 17,873. d. Nonrequested distribution. (1) Nonrequested mail subscriptions stated on PS Form 3541: 19,481. (2) Nonrequested copies distributed through the USPS by other classes of mail: 0. (3) Nonrequested copies distributed outside the mail: 0. e. Total nonrequested distribution: 19,481. f. Total distribution: 37,354. g. Copies not distributed: 150. h. Total: 37,504. i. Percent paid and/or requested circulation: 47.66%. 16. Publication of Statement of Ownership for a requestor publication is required and will be printed in the November 2009 issue of this publication. 17. Signature and title of Editor, Publisher, Business Manager, or Owner: Alan J. Imhoff, President, IMNG.

to rest the other issues and concerns.” One concern is that the retail clinics may usurp or interrupt a patient’s relationship with his or her primary care physician. Both Dr. Ejnes and Dr. Epperly said that an acute care visit for a UTI, for example, provides an occasion for the physician to delve into other health issues, including chronic conditions. That would not occur at a retail clinic, they said.

Lead author Dr. Ateev Mehrotra of the University of Pittsburgh said the potential for undermining the patient’s relationship with the primary care physician is a valid concern. He hopes to look at this aspect of retail clinics in future studies, Dr. Mehrotra said in an interview.

For this study, the costs were calculated by aggregating claims into episodes of care. Episodes were categorized according to where the first visit occurred. Retail clinic episodes were matched with episodes in the other settings. Overall, there were 15,170 episodes of care, with 2,100 occurring in retail settings, 6,211 in physician offices, 5,880 in urgent care centers, and 979 in emergency departments. The cost included the health plan reimbursement plus co-payments.

To measure quality, the researchers created 14 indicators, derived from various sources. Aggregate quality scores were calculated by dividing all instances in which recommended care was delivered by the number of times patients were eligible to receive care in each setting.

The authors found that women and

high-income individuals accounted for the greatest number of retail clinic episodes.

The cost of care was “substantially” lower in retail clinics, at \$110, compared with \$166 in a physician’s office, \$156 in an urgent care center, and \$570 in an emergency department. Total costs over 12 months were \$1,236 for the retail clinic, \$1,435 for the physician office, and \$2,157 for the emergency department. The largest portion of the cost was for evaluation and management. Follow-up visits were similar across settings. Lab and imaging costs were lower in re-

tail clinics, primarily because they weren’t ordered as often.

Of the total 15,170 episodes, there were only 11 hospitalizations; two of the hospitalized patients had first gone to a retail clinic.

The quality scores were almost the same for retail clinics, physician offices, and urgent care centers, with clinics meeting 63% of the measures, physicians 61%, and urgent care centers 63%. Aggregate quality scores were lower for emergency departments, at 55%.

Dr. Mehrotra acknowledged that the study had many limitations, including

that the patients who were randomly selected happened to be healthier than the average HealthPartners enrollee. Also, there are no data indicating that the cost and quality findings for these conditions are true for other conditions. But Dr. Mehrotra said he had no reason to believe that the data could not be extrapolated to other simple, acute conditions.

The study was funded by the California HealthCare Foundation, an independent philanthropic organization. Dr. Mehrotra’s research is also supported by a National Institutes of Health career development grant.

Mirena® (levonorgestrel-releasing intrauterine system)

BRIEF SUMMARY
CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES

Rx only

INDICATIONS AND USAGE

Mirena is indicated for intrauterine contraception for up to 5 years. Thereafter, if continued contraception is desired, the system should be replaced. Mirena is recommended for women who have had at least one child.

CONTRAINDICATIONS

- Mirena is contraindicated when one or more of the following conditions exist:
- Pregnancy or suspicion of pregnancy.
 - Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity.
 - Acute pelvic inflammatory disease or a history of pelvic inflammatory disease unless there has been a subsequent intrauterine pregnancy.
 - Postpartum endometritis or infected abortion in the past 3 months.
 - Known or suspected uterine or cervical neoplasia or unresolved, abnormal Pap smear.
 - Genital bleeding of unknown etiology.
 - Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections until infection is controlled.
 - Acute liver disease or liver tumor (benign or malignant).
 - Conditions associated with increased susceptibility to pelvic infections.
 - A previously inserted IUD that has not been removed.
 - Hypersensitivity to any component of this product.
 - Known or suspected carcinoma of the breast.

WARNINGS

1. Ectopic Pregnancy

Evaluate women who become pregnant while using Mirena for ectopic pregnancy. Up to half of pregnancies that occur with Mirena in place are ectopic. The incidence of ectopic pregnancy in clinical trials that excluded women with risk factors for ectopic pregnancy was about 1 ectopic pregnancy per 1000 users per year.

Tell women who choose Mirena about the risks of ectopic pregnancy, including the loss of fertility. Teach them to recognize and report to their physician promptly any symptoms of ectopic pregnancy. Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry a higher risk of ectopic pregnancy.

The risk of ectopic pregnancy in women who have a history of ectopic pregnancy and use Mirena is unknown. Clinical trials of Mirena excluded women with a history of ectopic pregnancy.

2. Intrauterine Pregnancy

If pregnancy should occur with Mirena in place, Mirena should be removed. Removal or manipulation of Mirena may result in pregnancy loss. In the event of an intrauterine pregnancy with Mirena, consider the following:

- Septic abortion
In patients becoming pregnant with an IUD in place, septic abortion—with septicemia, septic shock, and death—may occur.

b. Continuation of pregnancy

If a woman becomes pregnant with Mirena in place and if Mirena cannot be removed or the woman chooses not to have it removed, she should be warned that failure to remove Mirena increases the risk of miscarriage, sepsis, premature labor and premature delivery. She should be followed closely and advised to report immediately any flu-like symptoms, fever, chills, cramping, pain, bleeding, vaginal discharge or leakage of fluid.

c. Long-term effects and congenital anomalies

When pregnancy continues with Mirena in place, long-term effects on the offspring are unknown. As of September 2006, 390 live births out of an estimated 9.9 million Mirena users had been reported. Congenital anomalies in live births have occurred infrequently. No clear trend towards specific anomalies has been observed. Because of the intrauterine administration of levonorgestrel and local exposure of the fetus to the hormone, the possibility of teratogenicity following exposure to Mirena cannot be completely excluded. Some observational data support a small increased risk of masculinization of the external genitalia of the female fetus following exposure to progestins at doses greater than those currently used for oral contraception. Whether these data apply to Mirena is unknown.

3. Sepsis

As of September 2006, 9 cases of Group A streptococcal sepsis (GAS) out of an estimated 9.9 million Mirena users had been reported. In some cases, severe pain occurred within hours of insertion followed by sepsis within days. Because death from GAS is more likely if treatment is delayed, it is important to be aware of these rare but serious infections. Aseptic technique during insertion of Mirena is essential. GAS sepsis may also occur postpartum, after surgery, and from wounds.

4. Pelvic Inflammatory Disease (PID)

Mirena is contraindicated in the presence of known or suspected PID or in women with a history of PID unless there has been a subsequent intrauterine pregnancy. Use of IUDs has been associated with an increased risk of PID. The highest risk of PID occurs shortly after insertion (usually within the first 20 days thereafter) (see **PRECAUTIONS, Insertion Precautions**). A decision to use Mirena must include consideration of the risks of PID.

- Women at increased risk for PID
PID is often associated with a sexually transmitted disease, and Mirena does not protect against sexually transmitted disease. The risk of PID is greater for women who have multiple sexual partners, and also for women whose sexual partner(s) have multiple sexual partners. Women who have had PID are at increased risk for a recurrence or re-infection.
- PID warning to Mirena users
All women who choose Mirena must be informed prior to insertion about the possibility of PID and that PID can cause tubal damage leading to ectopic pregnancy or infertility, or infrequently can necessitate hysterectomy, or cause death. Patients must be taught to recognize and report to their physician promptly any symptoms of pelvic inflammatory disease. These symptoms include development of menstrual disorders (prolonged or missed periods), unusual vaginal discharge, abdominal or pelvic pain or tenderness, dyspareunia, chills, and fever.

- Asymptomatic PID
PID may be asymptomatic but still result in tubal damage and its sequelae.
- Treatment of PID
Following a diagnosis of PID, or suspected PID, bacteriologic specimens should be obtained and antibiotic therapy should be initiated promptly. Removal of Mirena after initiation of antibiotic therapy is usually appropriate. Guidelines for PID treatment are available from the Centers for Disease Control (CDC), Atlanta, Georgia. Actinomycosis has been associated with IUDs. Symptomatic women with IUDs should have the IUD removed and should receive antibiotics. However, the management of the asymptomatic carrier is controversial because actinomycetes can be found normally in the genital tract cultures in healthy women without IUDs. False positive findings of actinomycosis on Pap smears can be a problem. When possible, confirm the Pap smear diagnosis with cultures.

5. Irregular Bleeding and Amenorrhea

Mirena can alter the bleeding pattern and result in spotting, irregular bleeding, heavy bleeding, oligomenorrhea and amenorrhea. During the first three to six months of Mirena use, the number of bleeding and spotting days may be increased and bleeding patterns may be irregular. Thereafter the number of bleeding and spotting days usually decreases but bleeding may remain irregular. If bleeding irregularities develop during prolonged treatment, appropriate diagnostic measures should be taken to rule out endometrial pathology. Amenorrhea develops in approximately 20% of Mirena users by one year. The possibility of pregnancy should be considered if menstruation does not occur within six weeks of the onset of previous menstruation. Once pregnancy has been excluded, repeated pregnancy tests are generally not necessary in amenorrheic women unless indicated, for example, by other signs of pregnancy or by pelvic pain.

6. Embedment

Embedment of Mirena in the myometrium may occur. Embedment may decrease contraceptive effectiveness and result in pregnancy (see **WARNINGS, Ectopic Pregnancy and Intrauterine Pregnancy**). An embedded Mirena should be removed. Embedment can result in difficult removal and, in some cases surgical removal may be necessary.

7. Perforation

Perforation or penetration of the uterine wall or cervix may occur during insertion although the perforation may not be detected until some time later. If perforation occurs, pregnancy may result (see **WARNINGS, Ectopic Pregnancy and Intrauterine Pregnancy**). Mirena must be located and removed; surgery may be required. Delayed detection of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses and erosion of adjacent viscera.

The risk of perforation may be increased in lactating women, in women with fixed retroverted uterus, and in women with postpartum uterine involution. To decrease the risk of perforation postpartum, Mirena insertion should be delayed a minimum of 6 weeks after delivery or until uterine involution is complete. If involution is substantially delayed, consider waiting until 12 weeks postpartum. Inserting Mirena immediately after first trimester abortion is not known to increase the risk of perforation, but insertion after second trimester abortion should be delayed until uterine involution is complete.

8. Expulsion

Partial or complete expulsion of Mirena may occur (see **PRECAUTIONS, Continuation and Removal**).

Symptoms of the partial or complete expulsion of any IUD may include bleeding or pain. However, the system can be expelled from the uterine cavity without the woman noticing it. Partial expulsion may decrease the effectiveness of Mirena. As menstrual flow typically decreases after the first 3 to 6 months of Mirena use, an increase of menstrual flow may be indicative of an expulsion. If expulsion has occurred, Mirena may be replaced within 7 days of a menstrual period after pregnancy has been ruled out.

9. Ovarian Cysts

Since the contraceptive effect of Mirena is mainly due to its local effect, ovulatory cycles with follicular rupture usually occur in women of fertile age using Mirena. Sometimes atresia of the follicle is delayed and the follicle may continue to grow. Enlarged follicles have been diagnosed in about 12% of the subjects using Mirena. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia. In most cases the enlarged follicles disappear spontaneously during two to three months observations. Persistent enlarged follicles should be evaluated. Surgical intervention is not usually required.

10. Breast Cancer

Women who currently have or have had breast cancer, or have a suspicion of breast cancer, should not use hormonal contraception because breast cancer is a hormone-sensitive tumor.

Spontaneous reports of breast cancer have been received during postmarketing surveillance with Mirena. Because spontaneous reports are voluntary and of a population of uncertain size, it is not possible to use post-marketing data to reliably estimate the frequency or establish causal relationship to drug exposure. Two observational studies have not provided evidence of an increased risk of breast cancer during the use of Mirena.

11. Risks of Mortality

The available data from a variety of sources have been analyzed to estimate the risk of death associated with various methods of contraception. These estimates include the combined risk of the contraceptive method plus the risk of pregnancy or abortion in the event of method failure. The findings of the analysis are shown in Table 1.

Table 1: Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility per 100,000 Nonsterile Women, by Fertility Control Method According to Age

METHODS	AGE GROUP					
	15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years
No Birth Control Method/Term	4.7	5.4	4.8	6.3	11.7	20.6
No Birth Control Method/Abortion	2.1	2.0	1.6	1.9	2.8	5.3
IUD	0.2	0.3	0.2	0.1	0.3	0.6
Periodic Abstinence	1.4	1.3	0.7	1.0	1.0	1.9
Withdrawal	0.9	1.7	0.9	1.3	0.8	1.5
Coitus Interruptus	0.6	1.2	0.6	0.9	0.5	1.0
Diaphragm/Cap	0.6	1.4	0.6	0.9	1.6	3.1
Sponge	0.8	1.5	0.8	1.1	2.2	4.1
Spermicides	1.6	1.9	1.4	1.9	1.5	2.7
Oral Contraceptives	0.8	1.3	1.1	1.8	1.0	1.9
Implants/Injectables	0.2	0.6	0.5	0.8	0.5	0.6
Tubal Sterilization	1.3	1.2	1.1	1.1	1.2	1.3
Vasectomy	0.1	0.1	0.1	0.1	0.1	0.2

Harlap S. et al., Preventing Pregnancy, protecting health: a new look at birth control choices in the US. The Alan Guttmacher Institute 1991: 1-129

PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES.

1. Patient Counseling Information

Prior to insertion, give the patient the Patient Information Booklet. She should be given the opportunity to read the information and discuss fully any questions she may have concerning Mirena as well as other methods of contraception. Also, advise the patient that the prescribing information is available to her upon request.

Careful and objective counseling of the patient prior to insertion regarding the expected bleeding pattern, the possible inter-individual variation in changes in bleeding, including amenorrhea, and the etiology of the changes may have an effect on the frequency of patient-requested removal.

The patient should be informed that some bleeding such as irregular or prolonged bleeding and spotting, and/or cramps may occur during the first few weeks after insertion. If her symptoms continue or are severe she should report them to her healthcare provider. She should also be given instructions on what other symptoms require her to call her healthcare provider. She should be instructed on how to check after her menstrual period to make certain that the threads still protrude from the cervix and cautioned not to pull on the threads and displace Mirena. She should be informed that there is no contraceptive protection if Mirena is displaced or expelled.

2. Patient Evaluation and Clinical Considerations

a. A complete medical and social history, including that of the partner, should be obtained to determine conditions that might influence the selection of an IUD for contraception (see **CONTRAINDICATIONS**).

NOTE: Special attention must be given to ascertaining whether the woman is at increased risk of infection (for example, leukemia, acquired immune deficiency syndrome (AIDS), IV drug abuse), or has a history of PID unless there has been a subsequent intrauterine pregnancy. Mirena is contraindicated in these women.

b. A physical examination should include a pelvic examination, a Pap smear, examination of the breasts, and appropriate tests for any other forms of genital or other sexually transmitted diseases, such as gonorrhea and chlamydia laboratory evaluations, if indicated. Use of Mirena in patients with vaginitis or cervicitis should be postponed until proper treatment has eradicated the infection and until it has been shown that the cervicitis is not due to gonorrhea or chlamydia (see **CONTRAINDICATIONS**).

c. Irregular bleeding may mask symptoms and signs of endometrial polyps or cancer. Because irregular bleeding/spotting is common during the first months of Mirena use, exclude endometrial pathology prior to the insertion of Mirena in women with persistent or uncharacteristic bleeding. If unexplained bleeding irregularities develop during the prolonged use of Mirena, appropriate diagnostic measures should be taken. (See **WARNINGS, Irregular Bleeding and Amenorrhea**.)

d. The healthcare provider should determine that the patient is not pregnant. The possibility of insertion of Mirena in the presence of an existing undetermined pregnancy is reduced if insertion is performed within 7 days of the onset of a menstrual period. Mirena can be replaced by a new system at any time in the cycle. Mirena can be inserted immediately after first trimester abortion.

e. Mirena should not be inserted until 6 weeks postpartum or until involution of the uterus is complete in order to reduce the incidence of perforation and expulsion. If involution is substantially delayed, consider waiting until 12 weeks postpartum (see **WARNINGS, Perforation**).

f. Patients with certain types of valvular or congenital heart disease and surgically constructed systemic-pulmonary shunts are at increased risk of infective endocarditis. Use of Mirena in these patients may represent a potential source of septic emboli. Patients with known congenital heart disease who may be at increased risk should be treated with appropriate antibiotics at the time of insertion and removal.

g. Patients requiring chronic corticosteroid therapy or insulin for diabetes should be monitored with special care for infection.

h. Mirena should be used with caution in patients who have:

- coagulopathy or are receiving anticoagulants
- migraine, focal transient cerebral ischemia or other symptoms indicating transient cerebral ischemia
- exceptionally severe headache
- marked increase of blood pressure
- severe arterial disease such as stroke or myocardial infarction

3. Insertion Precautions

a. Observe strict asepsis during insertion. The presence of organisms capable of establishing PID can be determined by appearance, and IUD insertion may be associated with introduction of vaginal bacteria into the uterus. Administration of antibiotics may be considered, but the utility of this treatment is unknown.

b. Carefully sound the uterus prior to Mirena insertion to determine the degree of patency of the endocervical canal and the internal os, and the direction and depth of the uterine cavity. In occasional cases, severe cervical stenosis may be encountered. Do not use excessive force to overcome this resistance.

c. Fundal positioning of Mirena is important to prevent expulsion and maximize efficacy. Therefore, follow the instructions for the insertion carefully.

d. If the patient develops decreased pulse, perspiration, or pallor, have her remain supine until these signs resolve. Insertion may be associated with some pain and/or bleeding. Syncope, bradycardia, or other neurovascular episodes may occur during insertion of Mirena, especially in patients with a predisposition to these conditions or cervical stenosis.

4. Continuation and Removal

a. Reexamine and evaluate patients 4 to 12 weeks after insertion and once a year thereafter, or more frequently if clinically indicated.

b. If the threads are not visible, they may have retracted into the uterus or broken, or Mirena may have broken, perforated the uterus, or been expelled (see **WARNINGS, Perforation and Expulsion**). If the length of the threads has changed from the length at time of insertion, the system may have become displaced. Pregnancy must be excluded and the location of Mirena verified, for example, by sonography, X-ray, or by gentle exploration of the uterine cavity with a probe. If Mirena is displaced, remove it. A new Mirena may be inserted at that time or during the next menses if it is certain that conception has not occurred. If Mirena is in place with no evidence of perforation, no intervention is indicated.

c. Promptly examine users with complaints of pain, odorless discharge, unexplained bleeding (see **WARNINGS, Irregular Bleeding and Amenorrhea**), fever, genital lesions or sores.

d. Consider the possibility of ectopic pregnancy in the case of lower abdominal pain especially in association with missed periods or if an amenorrheic woman starts bleeding (see **WARNINGS, Ectopic Pregnancy**).

e. In the event a pregnancy is confirmed during Mirena use:

- Determine whether pregnancy is ectopic and, if so, take appropriate measures.
- Inform patient of the risks of leaving Mirena in place or removing it during pregnancy and of the lack of data on long-term effects on the offspring of women who have had Mirena in place during conception or gestation (see **WARNINGS, Intrauterine Pregnancy**).

f. If possible, Mirena should be removed after the patient has been warned of the risks of removal. If removal is difficult, the patient should be counseled and offered pregnancy termination.

g. Mirena should be removed for the following medical reasons:

- menorrhagia and/or metrorrhagia producing anemia
- acquired immune deficiency syndrome (AIDS)
- sexually transmitted disease
- pelvic infection: endometritis
- symptomatic genital actinomycosis
- intractable pelvic pain
- severe dyspareunia
- pregnancy
- endometrial or cervical malignancy
- uterine or cervical perforation

h. Removal of the system should also be considered if any of the following conditions arise for the first time:

- migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia
- exceptionally severe headache
- jaundice
- marked increase of blood pressure
- severe arterial disease such as stroke or myocardial infarction

i. Removal may be associated with pain and/or bleeding or neurovascular episodes.

5. **Glucose Tolerance**
Levonorgestrel may affect glucose tolerance, and the blood glucose concentration should be monitored in diabetic users of Mirena.

6. **Drug Interactions**
The influence of drugs on the contraceptive efficacy of Mirena has not been studied. The metabolism of progestogens may be increased by concomitant use of substances known to induce drug-metabolizing liver enzymes, specifically cytochrome P450 enzymes.

7. **Carcinogenesis**
Long-term studies in animals to assess the carcinogenic potential of levonorgestrel releasing intrauterine system have not been performed (see **WARNINGS**).

8. **Pregnancy**
Pregnancy Category X (see **WARNINGS**).

9. **Nursing Mothers**
In general, no adverse effects have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers, resulting in detectable steroid levels in infant plasma. Also, see **WARNINGS, Perforation**.

10. **Pediatric Use**
Safety and efficacy of Mirena have been established in women of reproductive age. Use of this product before menarche is not indicated.

11. **Geriatric Use**
Mirena has not been studied in women over age 65 and is not currently approved for use in this population.

12. **Return to Fertility**
About 80% of women wishing to become pregnant conceived within 12 months after removal of Mirena.

ADVERSE REACTIONS
The most serious adverse reactions associated with the use of Mirena are discussed above in the **WARNINGS and PRECAUTIONS** sections. Very common adverse reactions (>1/10 users) include: abnormal vaginal bleeding (including spotting, irregular bleeding, heavy bleeding, oligomenorrhea and amenorrhea) and ovarian cysts. Other adverse events are listed below using MedDRA (9.0) terms. Adverse reactions reported by 5% or more of clinical trial subjects include:

- Abdominal/pelvic pain
- Vaginal discharge
- Nausea
- Headache
- Nervousness
- Vulvovaginitis
- Dysmenorrhea
- Back pain
- Weight increase
- Breast pain/tenderness
- Acne
- Decreased libido
- Depressed mood
- Cervix/Papanicolaou smear normal, class II
- Hypertension

Other relevant reported adverse reactions occurring in less than 5% of subjects include: migraine, vomiting, anemia, dyspareunia, alopecia, eczema, pruritus, rash, urticaria, abdominal distention, altered mood, hirsutism, edema.

Postmarketing Experience
The following adverse reactions have been identified during post approval use of Mirena: device breakage and angiodema. Because these reactions are reported sporadically from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Manufactured for:

 **Bayer HealthCare Pharmaceuticals**

Bayer HealthCare Pharmaceuticals Inc.
Wayne, NJ 07470

Manufactured in Finland
Telephone number: 1-888-842-2937

© 2008, Bayer HealthCare Pharmaceuticals Inc. All rights reserved.
81179523 670510285 July 2008

INDEX OF ADVERTISERS

Bayer HealthCare Pharmaceuticals Inc.	
Mirena	6-8
Yaz	55-56
BD Diagnostics	
SurePath	9
CooperSurgical, Inc.	
Fetal Monitor	5
Duramed Pharmaceuticals, Inc. (a subsidiary of Barr Pharmaceuticals)	
ParaGard	20a-20b
ETHICON ENDO-SURGERY, Inc.	
Fetal Monitor	43
Fujirebio Diagnostics, Inc.	
HE4	23
GlaxoSmithKline	
Cervarix	3
Graceway Pharmaceuticals, LLC	
Aldara	13
Eli Lilly and Company	
Evista	30-33
Novo Nordisk Inc.	
Activella	23-24
Vagifem	37-38
Pfizer Inc.	
Tiozav	19-20
Proctor & Gamble Pharmaceuticals	
Actonel	14-17
Qiagen	
digene HPV test	45
Sanofi Pasteur Inc.	
Adacel	35-36
Schering Plough HealthCare Products, Inc.	
MiraLAX	25
Sciele Pharma, Inc.	
Prenate DHA	11-12
Watson Pharma, Inc.	
Gelnique	40-42